# PhiFlow First-Sale Market Audit
*Prepared: 2026-04-24*
*Purpose: satisfy T-004 with a buyer-safe market path before drafting T-005 pilot terms.*

## Executive Decision

Sell PhiFlow first as a **research instrument for semantic quantum workflows**, not as a general platform, wellness product, or finished SaaS.

The first buyer should be a quantum / AI research team that already understands experimental tools, accepts prototype friction, and values a verifiable hardware receipt more than a polished UI. The offer should be a fixed-scope pilot that turns one buyer-specific idea into:

1. a small `.phi` program,
2. emitted OpenQASM,
3. a simulator or IBM hardware run,
4. a reproducibility pack,
5. a concise "Gold Receipt" report.

## Buyer-Safe Positioning

**Primary line:** PhiFlow is a research-grade compiler/runtime for self-observing programs that can map high-level semantic constructs into OpenQASM circuits, sensor-conditioned execution, and signed runtime attestations.

**Short version:** Self-observing programs, compiled to quantum-capable workflows, with receipts.

**Do not lead with:** "consciousness as code," "quantum healing," "production-ready agent operating system," or "zero-install browser demo." Those may be internal or future narratives, but they create avoidable skepticism before the buyer understands the verified artifact.

## Evidence Baseline

| Claim | Status | Buyer-safe wording | Local evidence |
|---|---:|---|---|
| PhiFlow can emit OpenQASM for PhiIR programs | Confirmed | "PhiFlow has an OpenQASM emission path for supported programs." | `CLAIMS.md` C-8, `QSOP/STATE.md` 2026-03-13 |
| PhiFlow has run on IBM hardware | Confirmed, internal receipt exists | "A live IBM hardware run is recorded in project state; buyer-final receipt still needs raw IBM API/screenshot evidence attached." | `CLAIMS.md` C-10, `QSOP/STATE.md` 2026-04-14, `D:\CosmicFamily\EVIDENCE\PHIFLOW_IBM_HERON_20260414.md` |
| Latest local full test suite passed | Confirmed by fresh command | "Fresh local gate: 335 passed, 0 failed, 2 ignored on 2026-04-24; one compiler warning remains." | `cargo test -- --test-threads=1`, `QSOP/STATE.md` 2026-04-24 |
| Three-backend equivalence is achievable | Confirmed for supported programs | "Evaluator, PhiVM, and WASM conformance exists for supported programs." | `CLAIMS.md` C-2 |
| Hybrid signed handoffs exist | Confirmed by state | "Handoff events can be signed with hybrid classical + PQ signatures." | `QSOP/STATE.md` 2026-04-20 |
| Production-ready platform | Unsupported | Do not claim. Use "research-grade" and "pilot-ready." | `CLAIMS.md` unsupported claims |
| Zero-install browser demo | Unsupported | Do not claim. Browser host remains experimental/manual. | `CLAIMS.md` unsupported claims |

## Receipt Risk To Fix Before Buyer Delivery

`CLAIMS.md` and `QSOP/STATE.md` cite IBM job `d7euddh5a5qc73drdosg` on `ibm_fez` with 1024 shots and counts `0x0 -> 338`, `0x1 -> 686`.

`D:\CosmicFamily\EVIDENCE\PHIFLOW_IBM_HERON_20260414.md` now exists as the canonical internal receipt. It summarizes the job, source program, counts, and OpenQASM. It is still not buyer-final until a scrubbed raw IBM API JSON export or dashboard/PDF screenshot is attached.

**Action required before outreach with receipts:** attach raw/screenshot evidence to the internal receipt, or downgrade external wording to "recorded internally, raw export pending."

## Market Logic

### Why quantum research is the first market

IBM's public 2026 quantum roadmap emphasizes quantum-centric workflows that combine quantum computers with HPC, mapping/profiling tools, and use-case benchmarking. IBM also published a 2026 quantum-centric supercomputing reference architecture built around coordinated quantum/classical workflows and open software. That is the environment where PhiFlow's value is most legible: it is not replacing Qiskit; it is proposing a higher-level semantic layer that can produce auditable artifacts for that ecosystem.

OpenQASM is a credible bridge because IBM documentation describes OpenQASM 3 as a supported language surface and feature set for Qiskit / IBM Runtime, with important hardware restrictions. This means PhiFlow's marketing should say "emits OpenQASM artifacts for supported circuits," not "any semantic construct runs verbatim on hardware."

### Why agent infrastructure is second

The agentic AI market is noisy. Gartner warns that many agent projects will be canceled because of unclear value, cost, risk, or "agent washing." That makes PhiFlow's signed handoff / attestation story useful, but only if marketed as a governance and evidence layer around agents, not as another autonomous-agent platform.

### Why wellness is third, and only research-first

SOMA and biofeedback are interesting, but wellness claims carry regulatory and trust risk. FDA's general wellness policy centers on low-risk lifestyle functions unrelated to diagnosing, curing, mitigating, preventing, or treating disease. PhiFlow should not sell medical, therapeutic, or "quantum healing" outcomes. If used in biofeedback, sell it as an exploratory research instrumentation layer with no clinical claims.

## Use Cases Ranked For First Revenue

| Rank | Use case | Buyer pain | PhiFlow pilot deliverable | Why now |
|---:|---|---|---|---|
| 1 | Semantic quantum experiment compiler | Researchers work at circuit/tooling level and need faster ways to encode experimental intent | One buyer-specific `.phi` workflow that emits OpenQASM and runs through a simulator or IBM hardware path | Best fit to current verified IBM/OpenQASM evidence |
| 2 | Sensor-conditioned quantum workflow | Research teams want reproducible human-in-the-loop or environment-in-the-loop experiments | SOMA or telemetry signal mapped into a small circuit parameterization with a receipt | Differentiated, but must stay research-only |
| 3 | Signed agent handoff attestation | Agent teams lose provenance across handoffs | Hybrid signed handoff envelope + ledger receipt for one workflow | Practical, buyer-safe, no quantum overclaim required |
| 4 | Self-observing runtime for adaptive programs | Teams need pause/resume/evidence around evolving runtime state | Daemon snapshot, witness log, and replay report | Strong internal tech, but needs packaging |
| 5 | Edge telemetry coordination | Edge teams need local-first event coordination | MQTT resonance bus demo with signed local state reports | Plausible but less uniquely tied to the IBM receipt |

## Buyer Profiles

### Primary Buyer: Quantum / AI Research Lab

**Who:** university lab, IBM Quantum Network-style researcher, quantum algorithm team, applied quantum software group.

**Why they care:** They can evaluate weird research tools if the artifact is reproducible and the hardware path is real.

**Message:** "Give us one adaptive or semantic quantum experiment idea. We will encode it in PhiFlow, emit the circuit artifact, run the verification gate, and deliver a reproducibility pack."

### Secondary Buyer: Agent Infrastructure Team

**Who:** teams building multi-agent systems, internal AI governance, agent audit trails, research orchestration.

**Why they care:** They need context handoff evidence and replay protection more than another chat UI.

**Message:** "PhiFlow can treat agent handoffs as signed, observable runtime events instead of loose prompt transcripts."

### Tertiary Buyer: Biofeedback / Consciousness Research

**Who:** research institutes, labs, experimental biofeedback teams.

**Why they care:** They may value a formal language for sensor-conditioned experimental loops.

**Message:** "PhiFlow lets you define a sensor-conditioned protocol as executable code and collect a receipt. No medical claims, no therapeutic claims."

## Recommended Pilot Shape

**Name:** PhiFlow Gold Receipt Pilot

**Duration:** 6 to 8 weeks.

**Price anchor:** USD $25,000 to $35,000 for the first buyer. Use the existing `BUSINESS.md` range of $15,000 to $50,000, but do not start at the top of the range unless the pilot includes custom sensors, IBM hardware support, and substantial integration.

**Scope:** one buyer workflow, one artifact chain, one receipt report.

**Included:**

1. Discovery call and buyer workflow selection.
2. One `.phi` program implementing the selected workflow.
3. OpenQASM artifact for the quantum path where applicable.
4. Simulator run, and IBM hardware run if credentials/access permit.
5. Test/conformance report.
6. Receipt package with job ID, emitted artifacts, environment notes, and known limitations.
7. One handoff session explaining how to reproduce or extend the result.

**Excluded unless separately scoped:**

1. Clinical validation.
2. Production security certification.
3. Guaranteed quantum advantage.
4. Browser productization.
5. Ongoing managed hosting.
6. Any claim that physiological signals are cryptographic secrets or medical indicators.

## Transaction Requirements

| Requirement | Recommendation |
|---|---|
| Contract type | Fixed-scope professional services pilot |
| IP | MIT core stays open; custom buyer workflow can be delivered under a services agreement |
| Payment | 50% start, 50% on delivery of receipt pack |
| Acceptance | Artifact chain delivered and reproducible, not "quantum advantage" |
| Risk control | If IBM hardware access fails, deliver simulator/QASM pack and attempt hardware through buyer-provided access or reschedule the live run |
| Legal review | Needed before external use of warranty, refund, medical, or security claims |

## Marketing Copy That Is Safe To Use

### One-liner

PhiFlow turns self-observing program semantics into auditable runtime and quantum-workflow artifacts.

### Short pitch

PhiFlow is a research-grade compiler/runtime for programs that can witness their own state, preserve execution context, and emit quantum-capable workflow artifacts. The first pilot is simple: choose one research workflow, encode it in PhiFlow, run the verification gates, and deliver a reproducible receipt pack.

### Outreach paragraph

We have a small research compiler called PhiFlow that treats concepts like witness, coherence, and handoff as executable language constructs. The current value is not a polished SaaS dashboard. It is a reproducible artifact chain: `.phi` source, compiler output, OpenQASM where relevant, test evidence, and a live or simulator-backed receipt. I am looking for one research team with a concrete adaptive or semantic quantum workflow to turn into a fixed-scope pilot.

## Claims To Avoid

1. Do not say PhiFlow is production-ready.
2. Do not say it proves consciousness.
3. Do not say it provides quantum healing or therapeutic outcomes.
4. Do not say it guarantees quantum advantage.
5. Do not say all PhiFlow constructs run directly on IBM hardware.
6. Do not cite "0 warnings" unless a fresh command proves it.
7. Do not deliver the IBM receipt until the job ID mismatch is reconciled.

## Immediate Next Steps

1. Attach raw IBM API/screenshot evidence to the internal receipt for job `d7euddh5a5qc73drdosg`.
2. Remove or intentionally keep the current compiler warning; do not claim "zero warnings" until this is fixed.
3. Use `docs/pilot_offer.md` as the buyer-facing one-pager.
4. Create a separate "Gold Receipt" template after receipt reconciliation.
5. Pick one named buyer and send a narrow pilot ask, not the full architecture.

## External Sources Consulted

1. IBM Quantum Roadmap 2026: https://www.ibm.com/roadmaps/quantum/2026/
2. IBM quantum-centric supercomputing reference architecture announcement, 2026-03-12: https://newsroom.ibm.com/2026-03-12-ibm-releases-a-new-blueprint-for-quantum-centric-supercomputing
3. IBM Quantum OpenQASM 3 feature table: https://quantum.cloud.ibm.com/docs/en/guides/qasm-feature-table
4. IBM Qiskit OpenQASM 3 API documentation: https://quantum.cloud.ibm.com/docs/en/api/qiskit/qasm3
5. OpenQASM 3 paper: https://arxiv.org/abs/2104.14722
6. McKinsey Quantum Technology Monitor 2025: https://www.mckinsey.com/capabilities/tech-and-ai/our-insights/the-year-of-quantum-from-concept-to-reality-in-2025
7. Gartner agentic AI project-risk release, 2025-06-25: https://www.gartner.com/en/newsroom/press-releases/2025-06-25-gartner-predicts-over-40-percent-of-agentic-ai-projects-will-be-canceled-by-end-of-2027
8. FDA General Wellness: Policy for Low Risk Devices, January 2026: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-wellness-policy-low-risk-devices
